|
AKIRIN1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.0921999971103E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.04609998230876E-09 |
| Normal-vs-Stage2 |
4.24230000000136E-05 |
| Normal-vs-Stage3 |
3.21719983986668E-10 |
| Normal-vs-Stage4 |
5.70965497104226E-12 |
| Stage1-vs-Stage2 |
1.739370E-01 |
| Stage1-vs-Stage3 |
1.130410E-01 |
| Stage1-vs-Stage4 |
4.835100E-03 |
| Stage2-vs-Stage3 |
2.758100E-02 |
| Stage2-vs-Stage4 |
1.118280E-03 |
| Stage3-vs-Stage4 |
1.533410E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.13620002295534E-09 |
| Normal-vs-AfricanAmerican |
2.386100E-04 |
| Normal-vs-Asian |
2.77159994954701E-09 |
| Caucasian-vs-AfricanAmerican |
6.245400E-01 |
| Caucasian-vs-Asian |
4.838600E-01 |
| AfricanAmerican-vs-Asian |
3.806000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.17810017086617E-10 |
| Normal-vs-Female |
2.62940003104006E-09 |
| Male-vs-Female |
2.509200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.39590000564272E-09 |
| Normal-vs-Age(41-60Yrs) |
1.35880195983873E-12 |
| Normal-vs-Age(61-80Yrs) |
3.66440000565404E-09 |
| Normal-vs-Age(81-100Yrs) |
7.390200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.563200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.889400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.349000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.932200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.340800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.205800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.44890000000009E-05 |
| Classical-VS-Follicular |
1.193620E-01 |
| Classical-VS-Other |
2.024400E-01 |
| Classical-VS-Normal |
5.09709996432406E-09 |
| Tall-VS-Follicular |
1.82541000000036E-05 |
| Tall-VS-Other |
7.968400E-01 |
| Tall-VS-Normal |
2.15727435914914E-12 |
| Follicular-VS-Other |
1.189600E-01 |
| Follicular-VS-Normal |
1.44589999995226E-06 |
| Other-VS-Normal |
8.352600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.36079999782879E-09 |
| Normal-vs-N1 |
2.46558329308755E-12 |
| N0-vs-N1 |
1.504770E-03 |
|
|
